Lexaria Bioscience (LEXX) 10-Q 13 Jul 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	May 31, 2018	Jul. 13, 2018
Document Type	10-Q
Amendment Flag	false
Document Period End Date	May 31, 2018
Trading Symbol	lxrp
Entity Registrant Name	Lexaria Bioscience Corp.
Entity Central Index Key	1,348,362
Current Fiscal Year End Date	--08-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		73,144,805
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	May 31, 2018	Aug. 31, 2017
Current
Cash and cash equivalents	$ 2,063,369	$ 2,533,337
Marketable securities	17,617	0
Accounts and other receivable	267,777	45,293
Inventory	76,475	67,174
Prepaid expenses	161,882	149,691
Total Current Assets	2,587,120	2,795,495
Patents	120,567	62,827
Equipment	1,392	1,856
Total Noncurrent Assets	121,959	64,683
TOTAL ASSETS	2,709,079	2,860,178
Current
Accounts payable and accrued liabilities	62,533	32,574
Unearned revenue	0	17,083
Due to related parties	9,110	42,690
Total Current Liabilities	71,643	92,347
TOTAL LIABILITIES	71,643	92,347
STOCKHOLDERS' EQUITY
Share Capital Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Issued and outstanding: 72,397,305 common shares at May 31, 2018 and 67,975,761 common shares at August 31, 2017	72,397	67,976
Shares to be issued	500	0
Additional paid-in capital	21,123,864	16,108,270
Accumulated other comprehensive income	(7,383)	0
Deficit	(18,551,942)	(13,169,939)
Equity attributable to shareholders of the Company	2,637,436	3,006,307
Non-Controlling Interest	0	(238,476)
Total Stockholders' Equity	2,637,436	2,767,831
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,709,079	$ 2,860,178

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	May 31, 2018	Aug. 31, 2017
Common Stock, Shares Authorized	220,000,000	220,000,000
Common Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Issued	72,397,305	67,975,761
Common Stock, Shares, Outstanding	72,397,305	67,975,761

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017
Revenue	$ 140,340	$ 29,253	$ 336,933	$ 51,080
Cost of Goods Sold	2,427	9,183	22,239	24,943
Gross profit	137,913	20,070	314,694	26,137
Expenses
Accounting and audit	14,773	5,260	48,942	27,119
Depreciation and amortization	527	372	1,364	1,116
Advertising and promotions	175,770	73,271	432,494	124,080
Consulting	3,115,389	128,537	4,455,808	685,558
Interest expense	0	1,584	0	4,890
Investor relations	0	41,002	188	91,681
Legal and professional	65,091	46,367	207,134	115,851
Office and miscellaneous	64,779	41,578	182,754	112,435
Research and development	93,067	8,240	279,221	23,279
Travel	29,804	17,219	80,181	45,098
Gain on disposal of assets	0	0	(3,998)	0
Inventory write-off	3,625	726	12,609	4,651
Total Operating Expenses	3,562,825	364,156	5,696,697	1,235,758
Net loss for the period	(3,424,912)	(344,086)	(5,382,003)	(1,209,621)
Net loss attributable to:
Common shareholders	(3,424,912)	(339,130)	(5,382,003)	(1,182,357)
Non-controlling interest	$ 0	$ (4,956)	$ 0	$ (27,264)
Basic and diluted loss per share	$ (0.05)	$ (0.01)	$ (0.08)	$ (0.02)
Weighted average number of common shares outstanding
- Basic and diluted	71,042,049	60,635,704	70,239,898	55,968,504

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017
Net Loss	$ (3,424,912)	$ (344,086)	$ (5,382,003)	$ (1,209,621)
Other comprehensive loss
Unrealized loss on marketable securities	(7,383)	0	(7,383)	0
Comprehensive loss	$ (3,432,295)	$ (344,086)	$ (5,389,386)	$ (1,209,621)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	May 31, 2018	May 31, 2017
Cash flows used in operating activities
Net loss for the period	$ (5,382,003)	$ (1,209,621)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	2,102,704	36,642
Depreciation and amortization	1,364	1,116
Inventory write-off	12,609	4,651
Non-Cash Consideration for Licensing - revenue	(25,000)	0
Shares to be issued for services - consulting	640,000	0
Shares issued for services - consulting	183,426	71,760
Warrants issued for services - consulting	1,063,270	220,528
Change in working capital:
Accounts and other receivables	(222,484)	(19,815)
Inventory	(21,910)	1,692
Prepaid expenses	(12,191)	27,352
Accounts payable and accrued liabilities	29,959	(60,054)
Due to related parties	(33,580)	(273,925)
Unearned revenue	(17,083)	7,100
Net cash used in operating activities	(1,680,919)	(1,192,574)
Cash flows used in investing activities
Investment in Poviva	(70,000)	0
Patent Costs	(58,640)	(9,699)
Net cash used in investing activities	(128,640)	(9,699)
Cash flows from financing activities
Repayment of loan to a related party	0	(50,000)
Proceeds from issuance of equity	1,339,591	3,947,842
Net cash from financing activities	1,339,591	3,897,842
Increase (decrease) in cash	(469,968)	2,695,569
Cash, beginning of period	2,533,337	93,409
Cash, end of period	2,063,369	2,788,978
Supplemental information on cash flows:
Interest paid in cash	0	4,890
Income tax paid in cash	0	0
Common shares issued to settle accounts payable (shares issued for services)	12,000	53,000
Stock based compensation recognized in prepaid expenses	0	19,075
Reclassification of NCI to additional paid-in capital on acquisition	$ 238,476	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	COMMON STOCK [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	DEFICIT [Member]	NCI [Member]	AOCI [Member]	Total
Beginning Balance at Aug. 31, 2016	$ 51,288	$ 11,515,419	$ (11,300,662)	$ (178,288)		$ 87,757
Beginning Balance (Shares) at Aug. 31, 2016	51,288,477
Shares issued for services	$ 938	223,722				224,660
Shares issued for services (Shares)	939,354
Non-controlling Interest				(60,188)		(60,188)
Stock based compensation		93,968				93,968
Private placement of shares, net of issuance cost	$ 4,105	1,537,637				1,541,742
Private placement of shares, net of issuance cost (Shares)	4,104,280
Warrants issued for services		292,750				292,750
Exercise of stock options	$ 1,015	176,247				$ 177,262
Exercise of stock options (Shares)	1,014,125					1,014,125
Exercise of warrants	$ 10,322	2,222,710				$ 2,233,032
Exercise of warrants (Shares)	10,322,025
Conversion of debt	$ 308	45,817				46,125
Conversion of debt (Shares)	307,500
Net loss and comprehensive loss			(1,869,277)			(1,869,277)
Ending Balance at Aug. 31, 2017	$ 67,976	16,108,270	(13,169,939)	(238,476)		2,767,831
Ending Balance (Shares) at Aug. 31, 2017	67,975,761
Shares issued for services	$ 224	183,202				183,426
Shares issued for services (Shares)	223,690
Non-controlling Interest		(308,476)		$ 238,476		(70,000)
Shares to be issued for services	$ 500	639,500				640,000
Shares to be issued for services (Shares)	500,000
Stock based compensation		2,102,704				2,102,704
Warrants issued for services		1,063,270				1,063,270
Exercise of stock options	$ 298	70,904				$ 71,202
Exercise of stock options (Shares)	298,375					298,375
Exercise of warrants	$ 3,899	1,264,490				$ 1,268,389
Exercise of warrants (Shares)	3,899,479
Net loss and comprehensive loss						(5,389,386)
Net loss			(5,382,003)			(5,382,003)
Other Comprehensive income (loss)					$ (7,383)	(7,383)
Ending Balance at May. 31, 2018	$ 72,897	$ 21,123,864	$ (18,551,942)		$ (7,383)	$ 2,637,436
Ending Balance (Shares) at May. 31, 2018	72,897,305

Basis of Presentation

Basis of Presentation	9 Months Ended
	May 31, 2018
Basis of Presentation [Text Block]	1. Basis of Presentation The unaudited interim consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. These unaudited interim consolidated financial statements should be read in conjunction with the August 31, 2017 audited annual financial statements and notes thereto.

Organization, Business and Goin

Organization, Business and Going Concern	9 Months Ended
	May 31, 2018
Organization, Business and Going Concern [Text Block]	2. Organization, Business and Going Concern Lexaria Biosciences Corp. (“Lexaria”, or the “Company”) was formed on December 9, 2004 under the laws of the State of Nevada as an independent oil and gas company engaged in the exploration, development and acquisition of oil and gas properties in the United States and Canada. In March of 2014, the Company began its entry into the bioscience and alternative health and wellness business and discontinued its involvement in the oil and gas business in November 2014. In May 2016, the Company also commenced out-licensing its patented technology for improved delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company has its office in Kelowna, BC, Canada. On November 2, 2017, the Company announced it acquired 100% ownership interest in its majority owned subsidiary PoViva Tea, LLC (Note 9). The Company previously owned a 51% interest in PoViva Tea, LLC and acquired the remaining 49% interest. Compensation was $70,000, a waiver on certain debts, and a 5%, 20 -year royalty on net profits of ViPova Tea TM The Company’s unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company requires additional funds to maintain its operations and developments. Management’s plans in this regard are to raise equity and debt financing as required, but there is no certainty that such financing will be available or that it will be available at acceptable terms. The outcome of these matters cannot be predicted at this time.

Business Risk and Liquidity

Business Risk and Liquidity	9 Months Ended
	May 31, 2018
Business Risk and Liquidity [Text Block]	3. Business Risk and Liquidity The Company is subject to several categories of risk associated with its operating activities. The production and sale of alternative health products is an emerging industry in which business practices are not yet standardized and are subject to frequent scrutiny and evaluation by federal, state, provincial, and municipal authorities, academics, and media outlets, among others. Although we intend to develop our businesses in accordance with best ethical practices, we may suffer negative publicity if we, our partners, contractors, or customers are found to have engaged in any environmentally insensitive practices or other business practices that are viewed as unethical. Our operations may require licenses and permits from various governmental authorities. We believe that we will be able to obtain all necessary licenses and permits under applicable laws and regulations for our operations and believe we will be able to comply in all material respects with the terms of such licenses and permits. However, such licenses and permits are subject to change in various circumstances. There can be no guarantee that we will be able to obtain or maintain all necessary licenses and permits, and failing to obtain or retain required licenses could have a materially adverse effect on the Company. Lexaria and its subsidiaries are not involved directly or indirectly in the cultivation, processing, distribution, or utilization of Cannabis or Cannabis derived components. All of Lexaria’s consumer products utilize legally sourced Hemp and Hemp components in their production. Lexaria does have an ancillary involvement risk via out-licensing of its patented technology to licensees that choose to utilize its technology to manufacture products that contain locally or state approved but federally regulated and controlled contents. There can be no guarantee that changes in the regulatory framework and environment will not occur and such changes could have a materially adverse effect on the Company. It is possible some jurisdictions may even interpret Lexaria’s ancillary involvement as in contravention with regulations.

Basis of Consolidation

Basis of Consolidation	9 Months Ended
	May 31, 2018
Basis of Consolidation [Text Block]	4. Basis of Consolidation The unaudited interim consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiary, Lexaria CanPharm Corp. which was incorporated on April 4, 2014 under the laws of Canada, and wholly-owned subsidiary PoViva Tea, LLC (2017 - 51% owned) which was incorporated on December 12, 2014, under the laws of the State of Nevada. All significant inter-company balances and transactions have been eliminated.

Estimates and Judgments

Estimates and Judgments	9 Months Ended
	May 31, 2018
Estimates and Judgments [Text Block]	5. Estimates and Judgments The preparation of financial statements in conformity with U.S GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, and expenses. The estimates and the associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. In preparing these unaudited interim consolidated financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended August 31, 2017, with the addition of: Marketable Securities All marketable securities have been classified as “available for sale” and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (expense), net. The Company regularly evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before their recovery. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its marketable securities.

Recent Accounting Guidance

Recent Accounting Guidance	9 Months Ended
	May 31, 2018
Recent Accounting Guidance [Text Block]	6. Recent Accounting Guidance Effective March 1, 2018, the Company began recognizing revenue in accordance with FASB ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The Company adopted ASC 606 utilizing the modified retrospective method, meaning the cumulative effect of applying the standard was recognized to opening retained earnings as of September 1, 2017 with $NIL effect. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. In January 2016, FASB issued an ASU, Subtopic 825-10, to amend certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. Most prominent among the amendments is the requirement for changes in fair value of equity investments, with certain exceptions, to be recognized through profit or loss rather than other comprehensive income. The new standard will be effective for the Company beginning September 1, 2018. We estimate an $8,000 impact on the Company’s financial statements upon implementation. In February 2016 FASB issued ASU No. 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation, and disclosure of leases for both lessees and the lessors. The new standard requires the lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. The classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. When adopted, the Company does not expect this guidance to have a material impact on its consolidated financial statements. In June 2016, the FASB issued an ASU No 2016-13 (Topic 326) to replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss credit loss estimates. For trade and other receivables, loans and other financial instruments, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses which reflects losses that are probable. Credit losses relating to available for sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The new standard will be effective for Lexaria beginning September 1, 2020, with early adoption permitted. Application of the amendments is through a cumulative-effect adjustment to deficit as of the effective date. The Company is currently assessing the impact of the standard on its consolidated financial statements. However, to date the Company has not recognized any credit losses. In February 2018, the FASB issued ASU No. 2018-02, Income Statement–Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act enacted by the U.S. federal government on December 22, 2017 (the “2017 Tax Act”). Consequently, the amendments eliminate the stranded tax effects resulting from the 2017 Tax Act and will improve the usefulness of information reported to financial statement users. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period, (1) for public business entities for reporting periods for which financial statements have not yet been issued and (2) for all other entities for reporting periods for which financial statements have not yet been made available for issuance. The Company is currently evaluating the effect this ASU will have on its consolidated financial statements and related disclosures, but does not expect it to have a material impact on its consolidated financial statements.

Accounts and Other Receivable

Accounts and Other Receivable	9 Months Ended
	May 31, 2018
Accounts and Other Receivable [Text Block]	7. Accounts and Other Receivables May 31 August 31 2018 2017 $ $ Trade and deposits receivable 1,556 1,778 Territory License Fees receivable (Note 13) 222,347 - Sales tax receivable 43,874 43,515 267,777 45,293

Inventory

Inventory	9 Months Ended
	May 31, 2018
Inventory [Text Block]	8. Inventory May 31 August 31 2018 2017 $ $ Raw materials 18,870 14,220 Work in progress 41,044 10,688 Finished goods 16,561 42,266 76,475 67,174 During the nine month period ended May 31, 2018, the Company wrote down $12,609 (2017 - $4,651) of inventory to reflect its estimated net realizable value.

Alternative Health Products

Alternative Health Products	9 Months Ended
	May 31, 2018
Alternative Health Products [Text Block]	9. Alternative Health Products On November 12, 2014, the Company signed an agreement with Poppy’s Teas LLC (“PoViva”) and acquired 51% of ViPova™. On November 2, 2017, Lexaria announced that it acquired a 100% ownership interest in PoViva Tea, LLC, via cash compensation of $70,000, a waiver on certain debts owed to Lexaria, and a 5%, 20 -year royalty on net profits of ViPova Tea TM On August 11, 2015, Lexaria signed a license agreement with PoViva Tea LLC for $10,000, granting Lexaria a 35 -year non exclusive worldwide license to unencumbered use of PoViva Tea LLC’s IP Rights, including rights of resale. This license agreement ensured at that time that Lexaria had full access to the underlying patent pending infusion Technology (the “Technology”). Patents On December 12, 2017, Lexaria received patent US 9,839,612 B2 from the United States Patent and Trademark Office (“USPTO”) for the use of its technology as a delivery platform for all cannabinoids including THC; fat soluble vitamins; non steroidal anti-inflammatory pain medications (“NSAIDs”); and nicotine. On March 22, 2018 the Company announced it received a new Notice of Allowance from the USPTO providing for “composition of matter” claims that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids. On May 22, 2018 patent US 9,974,739 B2, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” was granted. On April 11, 2018 the Company announced it received a new Notice of Allowance from the USPTO providing claims that protect processes for making specific compositions of matter for enhanced cannabinoid delivery utilizing its DehydraTECH™ technology. On May 15, 2018 patent US 9,972,680 B2, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” was granted. Issued Patent # Patent Patent Family US 9,474,725 B1 10/25/2016 Food and Beverage Compositions Infused With US 9,839,612 B2 12/12/2017 US 9,972,680 B2 5/15/2018 US 9,974,739 B2 5/22/2018 A continuity schedule for patents is presented below: May 31 August 31 2018 2017 $ $ Balance – Beginning 62,827 53,997 Additions 58,640 9,699 Amortization* (900 ) (869 ) Balance – Ending 120,567 62,827 * The patents are amortized over their legal life of 20 years.

Unearned Revenue

Unearned Revenue	9 Months Ended
	May 31, 2018
Unearned Revenue [Text Block]	10. Unearned Revenue On May 14, 2016, the Company entered into a licensing agreement (the “Licensing Agreement”) with an arm’s length party (the “Licensee”) allowing the Licensee, for a two-year period, to utilize the Company’s Technology to create, test, manufacture, and sell marijuana-infused consumable and/or topical products, in the state of Colorado, with an option of extending the terms of the Licensing Agreement to Washington, Oregon, and California (the “Territorial License”). In addition to the granting of the license, the Company is required to provide support services to the Licensee in connection with the use of the Company’s Technology during the term of the Licensing Agreement. The Company determined that the provision of the support services were a separate deliverable under the licensing agreement. As the support services are not to be sold on a stand-alone basis, the Company was unable to establish a vendor-specific objective evidence of fair value of such services to be able to objectively allocate the Territory License fee receipts between the license and the support services. Accordingly, the Company recognized revenue on a pro-rated basis over the term of the Licensing agreement. The Company has since determined that the support services form an insignificant portion of the licensing contract as they are primarily completed prior to delivery of the technology and that delivery of the license is complete when the Technology is transferred to the Licensee. During the nine month period ended May 31, 2018, the Company recognized $17,083 (Note 13), of unearned revenue. A continuity schedule of unearned revenue is presented below: May 31 August 31 2018 2017 $ $ Balance – Beginning 17,083 12,500 Territorial License fees received - 30,000 Advance payments on product sales - 4,900 Earned revenue (17,083 ) (30,317 ) Balance - Ending - 17,083

Common Shares and Warrants

Common Shares and Warrants	9 Months Ended
	May 31, 2018
Common Shares and Warrants [Text Block]	11. Common Shares and Warrants Fiscal 2018 Activity On October 27, 2017 the Company extended the expiration date of warrants originally issued on January 9, 2017, with a one-year expiration date. The warrant quantity and exercise price remain unchanged, 500,000 warrants exercisable at $0.44, will now expire on January 9, 2019. There was a $Nil effect on the modification of the warrants. December 1, 2017, Lexaria issued 14,634 restricted common shares at a price of $0.82 per shares to settle $12,000 of debt to a director of the Company (shares issued for services). The Company awarded a total of 209,056 restricted common shares at an issuance price of $0.82 for a value of $171,426 as required by intellectual property performance thresholds within an existing management consulting contract with the Company divided between three officers and three managers. Lexaria awarded 250,000 warrants with an exercise price of $0.83 and an expiration date of December 1, 2019 to a manager of the Company, pursuant to a management contract. The warrants were valued at $124,476 and included in consulting expense. January 17, 2018 the Company announced that it has engaged JGRNT Capital Corp to provide strategic consulting services to the Company for a one-year term and awarded 500,000 warrants, each valid to purchase one common share at a price of $1.83 and valid for two years. The warrants were valued at $567,647 and included in consulting expense. May 28, 2018, the Company announced it entered into a consulting contract granting 250,000 warrants with an exercise price of $1.55 expiring three years after issuance. These warrants were valued at $319,699 and included in consulting expense. May 31, 2018, the Company accrued 500,000 shares to be issued, 250,000 shares at an issuance price of $1.24 and 250,000 shares at an issuance price of $1.32 for restricted common shares as required by intellectual property performance thresholds within existing management consulting contracts with the Company and $640,000 was included in consulting expense. During the period ended May 31, 2018 the Company recognized $51,488 in consulting expense for warrants previously granted to a consultant upon vesting. During the period ended May 31, 2018 the Company issued 35,913 warrants with an exercise price of $0.60 expiring April 3, 2019. These warrants were valued at $21,646 and recorded as a share issue cost within additional paid in capital for a net effect of $Nil. A continuity schedule for warrants is presented below: Weighted Average Number of Exercise Price Warrants $ Balance, August 31, 2016 12,136,241 0.18 Cancelled/Expired (1,004,150 ) 0.22 Exercised (10,322,025 ) 0.23 Issued 8,034,440 0.36 Balance, August 31, 2017 8,844,506 0.29 Cancelled/Expired (55,000 ) 0.27 Exercised (3,899,479 ) 0.33 Issued 1,035,913 1.48 Balance, May 31, 2018 5,925,940 0.49 The fair value of warrants granted as compensation warrants was estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: May 31 2018 Expected volatility 100% – 154% Risk-free interest rate 1.21%— 2.60% Expected life 1.21 – 3.00 years Dividend yield 0.00% Estimated fair value per warrant $0.40 – $1.28 A summary of warrants outstanding as of May 31, 2018 is presented below: # of Warrants Weighted Weighted Average Average Remaining Exercise Price Contractual Life $ 450,000 0.20 years 0.14 1,841,666 0.25 years 0.14 500,000 0.61 years 0.44 972,065 0.84 years 0.60 212,209 0.84 years 0.42 200,000 1.05 years 0.29 750,000 3.36 years 0.14 250,000 1.50 years 0.83 500,000 1.63 years 1.83 250,000 2.99 years 1.55 5,925,940 1.10 years 0.49

Stock Options

Stock Options	9 Months Ended
	May 31, 2018
Stock Options [Text Block]	12. Stock Options The Company has established its 2010 Stock Option Plan whereby the board of directors may, from time to time, grant up to 1,980,000 stock options to officers and employees, and its 2014 Stock Option Plan whereby the board of directors may grant up to 3,850,000 stock options to directors, officers, employees, and consultants. Stock options granted must be exercised no later than five years from the date of grant or such lesser period as determined by the Company’s board of directors. The exercise price of an option is equal to or greater than the closing market price of the Company’s common shares on the day preceding the date of grant. The vesting terms of each grant are set by the board of directors. Fiscal 2018 Activity On December 1, 2017, Lexaria granted 200,000 stock options with an exercise price of $0.83 and an expiration date of December 1, 2022 to an officer of the Company, pursuant to an existing management contract. The options were valued at $122,562 and included in consulting expense. On May 31, 2018, the Company announced that that pursuant to existing stock option plans, it has granted stock options to directors, officers, employees and consultants that enable the option holders to purchase up to 1,725,000 common shares of the Company at a price of $1.53 for a period of five years, vesting immediately. The options were valued at $1,980,142 and included in consulting expense. The fair value of options granted was estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: May 31 2018 Expected volatility 100% - 101% Risk-free interest rate 2.13% - 2.68% Expected life 5.00 years Dividend yield 0.00% Estimated fair value per warrant $0.61 - $1.15 A continuity schedule for stock options is presented below: Weighted Options Average Exercise Outstanding Price $ Balance, August 31, 2016 3,485,000 0.15 Exercised (1,014,125 ) 0.17 Granted 850,000 0.14 Balance, August 31, 2017 3,320,875 0.15 Exercised (298,375 ) 0.24 Granted 1,925,000 1.46 Balance, May 31, 2018 4,947,500 0.65 A summary of the stock options as at May 31, 2018, is presented below: Number of Stock Number of Stock Weighted Weighted Aggregate Options Options Average Average Intrinsic Value Exercisable Remaining Exercise Price Contractual Life $ $ 247,500 247,500 0.05 years 0.09 368,550 990,000 990,000 1.56 years 0.10 1,465,200 275,000 275,000 1.68 years 0.09 409,500 550,000 550,000 1.82 years 0.09 819,000 110,000 110,000 2.30 years 0.17 154,800 300,000 300,000 2.88 years 0.11 441,000 200,000 200,000 4.01 years 0.37 242,000 350,000 50,000 4.06 years 0.29 449,750 200,000 200,000 4.06 years 0.83 150,000 1,725,000 1,725,00 5.00 years 1.53 86,250 4,947,500 4,647,500 3.21 years 0.65 4,586,050

Revenues

Revenues	9 Months Ended
	May 31, 2018
Revenues [Text Block]	13. Revenues Nine Months Ended May 31 May 31 2018 2017 $ $ Product sales 14,188 12,932 Licensing revenue 321,683 37,392 Freight revenue 1,062 756 336,933 51,080 The Company recognized licensing revenue on a pro-rated basis over the term of the Licensing Agreement (Note 10) and additional licensing fees as they were earned. The Company has determined that the support services form an insignificant portion of the licensing contract as they are substantially completed prior to delivery of the Technology and that delivery of the license is complete when the Technology is transferred to the licensee. Additional licensing fees and royalties are recognized as they are earned. During the period ended May 31, 2018, the Company recognized $17,083 of deferred revenue (Note 10) and $304,600 of additional Licensing fees (Note 7). The additional Licensing fees consist of IP licensing fees for transfer of the Technology with the signing of definitive agreements for the DehydraTECH TM

Related Party Transactions

Related Party Transactions	9 Months Ended
	May 31, 2018
Related Party Transactions [Text Block]	14. Related Party Transactions For the period ended May 31, 2018 the Company paid/accrued the following: May 31 May 31 Cash Non-Cash 2018 Cash Non-Cash 2017 $ % $ % Total $ $ % $ % Total $ Management, consulting and accounting services: C.A.B Financial Services (1) 108,000 10% 1,002,705 90% 1,110,705 100,000 100% - 0% 100,000 M&E Services Ltd. (1) 58,140 10% 501,101 90% 559,241 35,311 100% - 0% 35,311 Docherty Management 106,067 Limited (1) 10% 968,329 90% 1,074,396 89,854 68% 42,000 32% 131,854 Company controlled by a director 12,000 17% 57,395 83% 69,395 36,000 100% - 0% 36,000 Director - 0% 57,395 100% 57,395 - 0% - 0% - 284,207 2,586,925 2,871,132 261,165 42,000 303,165 (1) The Company granted a total of 1,700,000 incentive stock options to officers and directors of the Company with a fair value of $1,844,425 and included in Consulting expense (Note 12). Due to related parties: As at May 31, 2018, $9,110 (August 31, 2017 - $42,690) was payable to related parties included in due to related parties. The related party transactions are recorded at the exchange amount established and agreed to between the related parties.

Segment Information

Segment Information	9 Months Ended
	May 31, 2018
Segment Information [Text Block]	15. Segment Information The Company’s operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property Licensing and Consumer Products. IP Licensing Consumer Products Corporate Consolidated Total External Revenue $ 321,683 $ 15,250 $ 336,933 Cost of Goods Sold - (22,239 ) - (22,239 ) Operating Expenses (1,712,237 ) (131,265 ) (3,853,195 ) (5,696,697 ) Segment Loss (1,390,554 ) (138,254 ) (3,853,195 ) (5,382,003 ) Total Assets 120,567 77,867 2,510,645 2,709,079

Commitments, Significant Contra

Commitments, Significant Contracts and Contingencies	9 Months Ended
	May 31, 2018
Commitments, Significant Contracts and Contingencies [Text Block]	16. Commitments, Significant Contracts and Contingencies Management Agreements As at May 31, 2018, the Company is party to the following contractual commitments: Party Monthly Commitment Expiry Date C.A.B Financial Services (1) (2) $12,000 November 30, 2018 Docherty Management Ltd. (1) (2) CAD $15,000 March 1, 2019 M&E Services Ltd. (1) CAD $8,000 June 1, 2018 Corporate Development(3) (4) CAD $4,000 Month to Month Corporate Development(3) (4) CAD $1,000 January 16, 2019 Advisory Agreement CAD $4,000 Month to Month Investor relations and communications – Alex Blanchard Capital(1) CAD $7,500 Month to Month Office Management (5) (6) CAD $6,500 December 1, 2019 Research & Development CAD $3,854 June 19, 2018 Revenue Incentive Milestones (1) Intellectual Property Milestones (2) Corporate Development Milestones (3) (4) Office Management Milestones (5) (6)

Prepaid Expenses

Prepaid Expenses	9 Months Ended
	May 31, 2018
Prepaid Expenses [Text Block]	17. Prepaid Expenses Prepaid expenses consist of the following at May 31, 2018 and August 31, 2017: May 31 August 31 2018 2017 $ $ Advertising & Conferences 98,385 106,682 Consulting Fees 8,841 23,984 Office & Insurance 17,046 15,062 Legal Fees 37,610 3,963 161,882 149,691

Marketable Securities

Marketable Securities	9 Months Ended
	May 31, 2018
Marketable Securities [Text Block]	18. Marketable Securities The components of Marketable Securities were as follows: Unrealized Cost Basis Unrealized Gains Losses Total August 31, 2017 Common Stock $ - $ - $ - $ - Total $ - $ - $ - $ - May 31, 2018 Common Stock 25,000 - (7,383 ) 17,617 Total $ 25,000 $ - ($7,383 ) $ 17,617 Unrealized losses from common stock are due to market price movements. Management does not believe any remaining unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence.

Subsequent Events

Subsequent Events	9 Months Ended
	May 31, 2018
Subsequent Events [Text Block]	19. Subsequent Events a) Subsequent to May 31, 2018, the Company issued 747,500 common shares from the exercise of 50,000 warrants at $0.60, 450,000 warrants at $0.14 and 247,500 stock options at $0.091 for a total of $115,500. b) On June 28, 2018, the Company announced it filed a new patent application with the United States Patent and Trademark Office for innovation in treatment options related to central nervous system disease or disorders titled: “Enhancement of Delivery of Lipophilic Active Agents Across the Blood- Brain Barrier and Methods for Treating Central Nervous System Disorders” under application number 62689096. c) Subsequent to May 31, 2018 the Company is forming new wholly-owned US subsidiary companies. Four new subsidiary companies are being created, one each for the market segments relating to pharmaceutical, hemp, nicotine, and cannabis-related applications.

Accounts and Other Receivable (

Accounts and Other Receivable (Tables)	9 Months Ended
	May 31, 2018
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	May 31 August 31 2018 2017 $ $ Trade and deposits receivable 1,556 1,778 Territory License Fees receivable (Note 13) 222,347 - Sales tax receivable 43,874 43,515 267,777 45,293

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	May 31, 2018
Schedule of Inventory, Current [Table Text Block]	May 31 August 31 2018 2017 $ $ Raw materials 18,870 14,220 Work in progress 41,044 10,688 Finished goods 16,561 42,266 76,475 67,174

Alternative Health Products (Ta

Alternative Health Products (Tables)	9 Months Ended
	May 31, 2018
Schedule of Finite-Lived Intangible Assets [Table Text Block]	May 31 August 31 2018 2017 $ $ Balance – Beginning 62,827 53,997 Additions 58,640 9,699 Amortization* (900 ) (869 ) Balance – Ending 120,567 62,827

Unearned Revenue (Tables)

Unearned Revenue (Tables)	9 Months Ended
	May 31, 2018
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	May 31 August 31 2018 2017 $ $ Balance – Beginning 17,083 12,500 Territorial License fees received - 30,000 Advance payments on product sales - 4,900 Earned revenue (17,083 ) (30,317 ) Balance - Ending - 17,083

Common Shares and Warrants (Tab

Common Shares and Warrants (Tables)	9 Months Ended
	May 31, 2018
Schedule of Capital Stock, Warrants [Table Text Block]	Weighted Average Number of Exercise Price Warrants $ Balance, August 31, 2016 12,136,241 0.18 Cancelled/Expired (1,004,150 ) 0.22 Exercised (10,322,025 ) 0.23 Issued 8,034,440 0.36 Balance, August 31, 2017 8,844,506 0.29 Cancelled/Expired (55,000 ) 0.27 Exercised (3,899,479 ) 0.33 Issued 1,035,913 1.48 Balance, May 31, 2018 5,925,940 0.49
Schedule of Stockholders' Equity Note, Warrants or Rights, Valuation Assumptions [Table Text Block]	May 31 2018 Expected volatility 100% – 154% Risk-free interest rate 1.21%— 2.60% Expected life 1.21 – 3.00 years Dividend yield 0.00% Estimated fair value per warrant $0.40 – $1.28
Schedule of Summary of Warrants Outstanding [Table Text Block]	# of Warrants Weighted Weighted Average Average Remaining Exercise Price Contractual Life $ 450,000 0.20 years 0.14 1,841,666 0.25 years 0.14 500,000 0.61 years 0.44 972,065 0.84 years 0.60 212,209 0.84 years 0.42 200,000 1.05 years 0.29 750,000 3.36 years 0.14 250,000 1.50 years 0.83 500,000 1.63 years 1.83 250,000 2.99 years 1.55 5,925,940 1.10 years 0.49

Stock Options (Tables)

Stock Options (Tables)	9 Months Ended
	May 31, 2018
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	May 31 2018 Expected volatility 100% - 101% Risk-free interest rate 2.13% - 2.68% Expected life 5.00 years Dividend yield 0.00% Estimated fair value per warrant $0.61 - $1.15
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Options Average Exercise Outstanding Price $ Balance, August 31, 2016 3,485,000 0.15 Exercised (1,014,125 ) 0.17 Granted 850,000 0.14 Balance, August 31, 2017 3,320,875 0.15 Exercised (298,375 ) 0.24 Granted 1,925,000 1.46 Balance, May 31, 2018 4,947,500 0.65
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Number of Stock Number of Stock Weighted Weighted Aggregate Options Options Average Average Intrinsic Value Exercisable Remaining Exercise Price Contractual Life $ $ 247,500 247,500 0.05 years 0.09 368,550 990,000 990,000 1.56 years 0.10 1,465,200 275,000 275,000 1.68 years 0.09 409,500 550,000 550,000 1.82 years 0.09 819,000 110,000 110,000 2.30 years 0.17 154,800 300,000 300,000 2.88 years 0.11 441,000 200,000 200,000 4.01 years 0.37 242,000 350,000 50,000 4.06 years 0.29 449,750 200,000 200,000 4.06 years 0.83 150,000 1,725,000 1,725,00 5.00 years 1.53 86,250 4,947,500 4,647,500 3.21 years 0.65 4,586,050

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	May 31, 2018
Revenue from External Customers by Products and Services [Table Text Block]	Nine Months Ended May 31 May 31 2018 2017 $ $ Product sales 14,188 12,932 Licensing revenue 321,683 37,392 Freight revenue 1,062 756 336,933 51,080

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	May 31, 2018
Schedule of Related Party Transactions [Table Text Block]	May 31 May 31 Cash Non-Cash 2018 Cash Non-Cash 2017 $ % $ % Total $ $ % $ % Total $ Management, consulting and accounting services: C.A.B Financial Services (1) 108,000 10% 1,002,705 90% 1,110,705 100,000 100% - 0% 100,000 M&E Services Ltd. (1) 58,140 10% 501,101 90% 559,241 35,311 100% - 0% 35,311 Docherty Management 106,067 Limited (1) 10% 968,329 90% 1,074,396 89,854 68% 42,000 32% 131,854 Company controlled by a director 12,000 17% 57,395 83% 69,395 36,000 100% - 0% 36,000 Director - 0% 57,395 100% 57,395 - 0% - 0% - 284,207 2,586,925 2,871,132 261,165 42,000 303,165

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	May 31, 2018
Schedule of Segment Reporting Information, by Segment [Table Text Block]	IP Licensing Consumer Products Corporate Consolidated Total External Revenue $ 321,683 $ 15,250 $ 336,933 Cost of Goods Sold - (22,239 ) - (22,239 ) Operating Expenses (1,712,237 ) (131,265 ) (3,853,195 ) (5,696,697 ) Segment Loss (1,390,554 ) (138,254 ) (3,853,195 ) (5,382,003 ) Total Assets 120,567 77,867 2,510,645 2,709,079

Commitments, Significant Cont36

Commitments, Significant Contracts and Contingencies (Tables)	9 Months Ended
	May 31, 2018
Long-term Purchase Commitment [Table Text Block]	Party Monthly Commitment Expiry Date C.A.B Financial Services (1) (2) $12,000 November 30, 2018 Docherty Management Ltd. (1) (2) CAD $15,000 March 1, 2019 M&E Services Ltd. (1) CAD $8,000 June 1, 2018 Corporate Development(3) (4) CAD $4,000 Month to Month Corporate Development(3) (4) CAD $1,000 January 16, 2019 Advisory Agreement CAD $4,000 Month to Month Investor relations and communications – Alex Blanchard Capital(1) CAD $7,500 Month to Month Office Management (5) (6) CAD $6,500 December 1, 2019 Research & Development CAD $3,854 June 19, 2018

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	9 Months Ended
	May 31, 2018
Schedule of Prepaid Expenses [Table Text Block]	May 31 August 31 2018 2017 $ $ Advertising & Conferences 98,385 106,682 Consulting Fees 8,841 23,984 Office & Insurance 17,046 15,062 Legal Fees 37,610 3,963 161,882 149,691

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	May 31, 2018
Marketable Securities [Table Text Block]	Unrealized Cost Basis Unrealized Gains Losses Total August 31, 2017 Common Stock $ - $ - $ - $ - Total $ - $ - $ - $ - May 31, 2018 Common Stock 25,000 - (7,383 ) 17,617 Total $ 25,000 $ - ($7,383 ) $ 17,617

Organization, Business and Go39

Organization, Business and Going Concern (Narrative) (Details) - PoViva Tea, LLC [Member] - USD ($)	1 Months Ended
	Nov. 30, 2017	May 31, 2018	Nov. 02, 2017	Oct. 31, 2017
Equity Method Investment, Ownership Percentage			100.00%	51.00%
Business Acquisition, Percentage of Voting Interests Acquired			49.00%
Payments to Acquire Businesses, Gross	$ 70,000
Royalty percentage		5.00%	5.00%
Term of Royalty contract	20 years
Royalty fair value			$ 0

Basis of Consolidation (Narrati

Basis of Consolidation (Narrative) (Details)	Nov. 02, 2017	Oct. 31, 2017
PoViva Tea, LLC [Member]
Equity Method Investment, Ownership Percentage	100.00%	51.00%

Recent Accounting Guidance (Nar

Recent Accounting Guidance (Narrative) (Details) - USD ($)	1 Months Ended
	Mar. 31, 2018	Jan. 31, 2016
Change in accounting policy, impact on financial statements	$ 0	$ 8,000

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended
	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017
Inventory Write-down	$ 3,625	$ 726	$ 12,609	$ 4,651

Alternative Health Products (Na

Alternative Health Products (Narrative) (Details) - USD ($)	1 Months Ended		9 Months Ended
	Nov. 30, 2017	Aug. 31, 2015	May 31, 2018	Nov. 02, 2017	Oct. 31, 2017
Finite-Lived Intangible Asset, Useful Life			20 years
PoViva Tea, LLC [Member]
Equity Method Investment, Ownership Percentage				100.00%	51.00%
Payments to Acquire Businesses, Gross	$ 70,000
Royalty percentage			5.00%	5.00%
Term of Royalty contract	20 years
Royalty fair value				$ 0
License Costs		$ 10,000
License agreement, term of contract		35 years

Unearned Revenue (Narrative) (D

Unearned Revenue (Narrative) (Details) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2018	Aug. 31, 2017
Earned revenue	$ 17,083	$ 30,317

Common Shares and Warrants (Nar

Common Shares and Warrants (Narrative) (Details)	9 Months Ended
	May 31, 2018USD ($)$ / sharesshares
Common Shares And Warrants 1 | shares	500,000
Common Shares And Warrants 2	$ 0.44
Common Shares And Warrants 3	$ 0
Common Shares And Warrants 4	14,634
Common Shares And Warrants 5 | $ / shares	$ 0.82
Common Shares And Warrants 6	$ 12,000
Common Shares And Warrants 7	209,056
Common Shares And Warrants 8	$ 0.82
Common Shares And Warrants 9	$ 171,426
Common Shares And Warrants 10 | shares	250,000
Common Shares And Warrants 11	$ 0.83
Common Shares And Warrants 12	$ 124,476
Common Shares And Warrants 13 | shares	500,000
Common Shares And Warrants 14	$ 1.83
Common Shares And Warrants 15	$ 567,647
Common Shares And Warrants 16 | shares	250,000
Common Shares And Warrants 17	$ 1.55
Common Shares And Warrants 18	$ 319,699
Common Shares And Warrants 19 | shares	500,000
Common Shares And Warrants 20 | shares	250,000
Common Shares And Warrants 21	$ 1.24
Common Shares And Warrants 22 | shares	250,000
Common Shares And Warrants 23	$ 1.32
Common Shares And Warrants 24	640,000
Common Shares And Warrants 25	$ 51,488
Common Shares And Warrants 26 | shares	35,913
Common Shares And Warrants 27	$ 0.60
Common Shares And Warrants 28	21,646
Common Shares And Warrants 29	$ 0

Stock Options (Narrative) (Deta

Stock Options (Narrative) (Details) - USD ($)	1 Months Ended		9 Months Ended	12 Months Ended
	May 31, 2018	Dec. 31, 2017	May 31, 2018	Aug. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,725,000	200,000	1,925,000	850,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.53	$ 0.83	$ 1.46	$ 0.14
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Fair Value	$ 1,980,142	$ 122,562
2010 Stock Option Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	1,980,000		1,980,000
2014 Stock Option Plan [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options	3,850,000		3,850,000

Revenues (Narrative) (Details)

Revenues (Narrative) (Details) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2018	Aug. 31, 2017
Earned revenue	$ 17,083	$ 30,317
Licensing fees	$ 304,600
Cannfections Group Inc. [Member]
Licensing fees, term of contract	7 years
NeutriSci International Inc. [Member]
Licensing fees, term of contract	2 years
Biolog, Inc. [Member]
Licensing fees, term of contract	5 years
GP Holdings LLC [Member]
Licensing fees, term of contract	5 years
Nuka Enterprises LLC [Member]
Licensing fees, term of contract	10 years
Nuka Enterprises LLC - Chocolate only [Member]
Licensing fees, term of contract	2 years

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($)	1 Months Ended		9 Months Ended	12 Months Ended
	May 31, 2018	Dec. 31, 2017	May 31, 2018	Aug. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,725,000	200,000	1,925,000	850,000
Due to related parties	$ 9,110		$ 9,110	$ 42,690
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures			1,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value			$ 1,844,425

Commitments, Significant Cont49

Commitments, Significant Contracts and Contingencies (Narrative) (Details)	9 Months Ended
	May 31, 2018USD ($)shares
Revenue Incentive Milestones [Member] | During first 12 months of the contract [Member]
Shares issuable by meeting milestone	100,000
Non-refundable revenues threshold | $	$ 200,000
Revenue Incentive Milestones [Member] | During the 13th to 24th months of the contract [Member]
Shares issuable by meeting milestone	50,000
Non-refundable revenues threshold | $	$ 200,000
Revenue Incentive Milestones [Member] | Any fiscal quarter during first 12 months of the contract [Member]
Shares issuable by meeting milestone	200,000
Non-refundable revenues threshold | $	$ 500,000
Revenue Incentive Milestones [Member] | Any fiscal quarter during the 13th to 24th months of the contract [Member]
Shares issuable by meeting milestone	100,000
Intellectual Property Milestones [Member]
Shares issuable by meeting milestone	250,000
Corporate Development Milestones 1 [Member] | During first 12 months of the contract [Member]
Shares issuable by meeting milestone	100,000
Non-refundable revenues threshold | $	$ 200,000
Corporate Development Milestones 1 [Member] | During the 13th to 24th months of the contract [Member]
Shares issuable by meeting milestone	50,000
Corporate Development Milestones 2 [Member] | During first 12 months of the contract [Member]
Shares issuable by meeting milestone	200,000
Non-refundable revenues threshold | $	$ 500,000
Corporate Development Milestones 2 [Member] | During the 13th to 24th months of the contract [Member]
Shares issuable by meeting milestone	100,000
Non-refundable revenues threshold | $	$ 500,000
Office Management Milestones 1 [Member] | Until December 1, 2018 [Member]
Shares issuable by meeting milestone	75,000
Non-refundable revenues threshold | $	$ 200,000
Office Management Milestones 1 [Member] | From December 2, 2018, until December 1, 2019 [Member]
Shares issuable by meeting milestone	40,000
Non-refundable revenues threshold | $	$ 200,000
Office Management Milestones 2 [Member] | Until December 1, 2018 [Member]
Shares issuable by meeting milestone	150,000
Non-refundable revenues threshold | $	$ 500,000
Office Management Milestones 2 [Member] | From December 2, 2018, until December 1, 2019 [Member]
Shares issuable by meeting milestone	80,000
Non-refundable revenues threshold | $	$ 500,000

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details)	9 Months Ended
	May 31, 2018USD ($)shares
Subsequent Events 1 | shares	747,500
Subsequent Events 2 | shares	50,000
Subsequent Events 3 | $	$ 0.60
Subsequent Events 4 | shares	450,000
Subsequent Events 5 | $	$ 0.14
Subsequent Events 6 | shares	247,500
Subsequent Events 7 | $	$ 0.091
Subsequent Events 8 | $	$ 115,500

Schedule of Accounts, Notes, Lo

Schedule of Accounts, Notes, Loans and Financing Receivable (Details) - USD ($)	May 31, 2018	Aug. 31, 2017
Trade and deposits receivable	$ 1,556	$ 1,778
Territory License Fee receivable	222,347	0
Sales tax receivable	43,874	43,515
Accounts and other receivable	$ 267,777	$ 45,293

Schedule of Inventory, Current

Schedule of Inventory, Current (Details) - USD ($)	May 31, 2018	Aug. 31, 2017
Raw materials	$ 18,870	$ 14,220
Finished goods	16,561	42,266
Work in progress	41,044	10,688
Inventory	$ 76,475	$ 67,174

Schedule of Finite-Lived Intang

Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2018	Aug. 31, 2017
Balance - Beginning	$ 62,827	$ 53,997
Additions	58,640	9,699
Amortization	(900)	(869)
Balance Ending	$ 120,567	$ 62,827

Deferred Revenue, by Arrangemen

Deferred Revenue, by Arrangement, Disclosure (Details) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2018	Aug. 31, 2017
Balance - Beginning	$ 17,083	$ 12,500
Territorial License fees received	0	30,000
Advance payments on product sales	0	4,900
Earned revenue	(17,083)	(30,317)
Balance - Ending	$ 0	$ 17,083

Schedule of Capital Stock, Warr

Schedule of Capital Stock, Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	May 31, 2018	Aug. 31, 2017
Class of Warrant or Right, Outstanding, Beginning of Period	8,844,506	12,136,241
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, Beginning of Period	$ 0.29	$ 0.18
Class of Warrant or Right, Expirations in Period	(55,000)	(1,004,150)
Class of Warrant or Right, Expirations in Period, Weighted Average Exercise Price	$ 0.27	$ 0.22
Class of Warrant or Right, Exercises in Period	(3,899,479)	(10,322,025)
Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price	$ 0.33	$ 0.23
Class of Warrant or Right, Grants in Period, Net of Forfeitures	1,035,913	8,034,440
Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price	$ 1.48	$ 0.36
Class of Warrant or Right, Outstanding, End of Period	5,925,940	8,844,506
Class of Warrant or Right, Outstanding, Weighted Average Exercise Price, End of Period	$ 0.49	$ 0.29

Schedule of Stockholders' Equit

Schedule of Stockholders' Equity Note, Warrants or Rights, Valuation Assumptions (Details)	9 Months Ended
	May 31, 2018USD ($)
Expected volatility	154.00%
Risk-free interest rate	2.60%
Expected life	3 years
Dividend yield	0.00%
Estimated fair value per warrant	$ 1.28
Minimum [Member]
Expected volatility	100.00%
Risk-free interest rate	1.21%
Expected life	1 year 2 months 16 days
Estimated fair value per warrant	$ 0.40

Schedule of Summary of Warrants

Schedule of Summary of Warrants Outstanding (Details)	9 Months Ended
	May 31, 2018$ / sharesshares
Number of Warrants | shares	5,925,940
Weighted Average Remaining Contractual Life	1 year 1 month 6 days
Weighted Average Exercise Price | $ / shares	$ 0.49
Warrants 1 [Member]
Number of Warrants | shares	450,000
Weighted Average Remaining Contractual Life	2 months 12 days
Weighted Average Exercise Price | $ / shares	$ 0.14
Warrants 2 [Member]
Number of Warrants | shares	1,841,666
Weighted Average Remaining Contractual Life	3 months
Weighted Average Exercise Price | $ / shares	$ 0.14
Warrants 3 [Member]
Number of Warrants | shares	500,000
Weighted Average Remaining Contractual Life	7 months 10 days
Weighted Average Exercise Price | $ / shares	$ 0.44
Warrants 4 [Member]
Number of Warrants | shares	972,065
Weighted Average Remaining Contractual Life	10 months 2 days
Weighted Average Exercise Price | $ / shares	$ 0.60
Warrants 5 [Member]
Number of Warrants | shares	212,209
Weighted Average Remaining Contractual Life	10 months 2 days
Weighted Average Exercise Price | $ / shares	$ 0.42
Warrants 6 [Member]
Number of Warrants | shares	200,000
Weighted Average Remaining Contractual Life	1 year 18 days
Weighted Average Exercise Price | $ / shares	$ 0.29
Warrants 7 [Member]
Number of Warrants | shares	750,000
Weighted Average Remaining Contractual Life	3 years 4 months 10 days
Weighted Average Exercise Price | $ / shares	$ 0.14
Warrants 8 [Member]
Number of Warrants | shares	250,000
Weighted Average Remaining Contractual Life	1 year 6 months
Weighted Average Exercise Price | $ / shares	$ 0.83
Warrants 9 [Member]
Number of Warrants | shares	500,000
Weighted Average Remaining Contractual Life	1 year 7 months 17 days
Weighted Average Exercise Price | $ / shares	$ 1.83
Warrants 10 [Member]
Number of Warrants | shares	250,000
Weighted Average Remaining Contractual Life	2 years 11 months 26 days
Weighted Average Exercise Price | $ / shares	$ 1.55

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	9 Months Ended
	May 31, 2018USD ($)
Expected life	5 years
Dividend yield	0.00%
Minimum [Member]
Expected volatility	100.00%
Risk-free interest rate	2.13%
Estimated fair value per option	$ 0.61
Maximum [Member]
Expected volatility	101.00%
Risk-free interest rate	2.68%
Estimated fair value per option	$ 1.15

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details)	9 Months Ended	12 Months Ended
	May 31, 2018$ / sharesshares	Aug. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning of Period	3,320,875	3,485,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning of Period | $ / shares	$ 0.15	$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(298,375)	(1,014,125)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares	$ 0.24	$ 0.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,925,000	850,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 1.46	$ 0.14
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, End of Period	4,947,500	3,320,875
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, End of Period | $ / shares	$ 0.65	$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,647,500

Schedule of Share-based Compe60

Schedule of Share-based Compensation Arrangements by Share-based Payment Award (Details)	9 Months Ended
	May 31, 2018USD ($)$ / sharesshares
Number of Stock Options	4,947,500
Number of Stock Options Exercisable	4,647,500
Weighted Average Remaining Contractual Life	3 years 2 months 16 days
Weighted Average Exercise Price | $ / shares	$ 0.65
Aggregate Intrinsic Value | $	$ 4,586,050
Stock Options 1 [Member]
Number of Stock Options	247,500
Number of Stock Options Exercisable	247,500
Weighted Average Remaining Contractual Life	18 days
Weighted Average Exercise Price | $ / shares	$ 0.09
Aggregate Intrinsic Value | $	$ 368,550
Stock Options 2 [Member]
Number of Stock Options	990,000
Number of Stock Options Exercisable	990,000
Weighted Average Remaining Contractual Life	1 year 6 months 22 days
Weighted Average Exercise Price | $ / shares	$ 0.10
Aggregate Intrinsic Value | $	$ 1,465,200
Stock Options 3 [Member]
Number of Stock Options	275,000
Number of Stock Options Exercisable	275,000
Weighted Average Remaining Contractual Life	1 year 8 months 5 days
Weighted Average Exercise Price | $ / shares	$ 0.09
Aggregate Intrinsic Value | $	$ 409,500
Stock Options 4 [Member]
Number of Stock Options	550,000
Number of Stock Options Exercisable	550,000
Weighted Average Remaining Contractual Life	1 year 9 months 25 days
Weighted Average Exercise Price | $ / shares	$ 0.09
Aggregate Intrinsic Value | $	$ 819,000
Stock Options 5 [Member]
Number of Stock Options	110,000
Number of Stock Options Exercisable	110,000
Weighted Average Remaining Contractual Life	2 years 3 months 18 days
Weighted Average Exercise Price | $ / shares	$ 0.17
Aggregate Intrinsic Value | $	$ 154,800
Stock Options 6 [Member]
Number of Stock Options	300,000
Number of Stock Options Exercisable	300,000
Weighted Average Remaining Contractual Life	2 years 10 months 17 days
Weighted Average Exercise Price | $ / shares	$ 0.11
Aggregate Intrinsic Value | $	$ 441,000
Stock Options 7 [Member]
Number of Stock Options	200,000
Number of Stock Options Exercisable	200,000
Weighted Average Remaining Contractual Life	4 years 4 days
Weighted Average Exercise Price | $ / shares	$ 0.37
Aggregate Intrinsic Value | $	$ 242,000
Stock Options 8 [Member]
Number of Stock Options	350,000
Number of Stock Options Exercisable	50,000
Weighted Average Remaining Contractual Life	4 years 22 days
Weighted Average Exercise Price | $ / shares	$ 0.29
Aggregate Intrinsic Value | $	$ 449,750
Stock Options 9 [Member]
Number of Stock Options	200,000
Number of Stock Options Exercisable	200,000
Weighted Average Remaining Contractual Life	4 years 22 days
Weighted Average Exercise Price | $ / shares	$ 0.83
Aggregate Intrinsic Value | $	$ 150,000
Stock Options 10 [Member]
Number of Stock Options	1,725,000
Number of Stock Options Exercisable	172,500
Weighted Average Remaining Contractual Life	5 years
Weighted Average Exercise Price | $ / shares	$ 1.53
Aggregate Intrinsic Value | $	$ 86,250

Revenue from External Customers

Revenue from External Customers by Products and Services (Details) - USD ($)	9 Months Ended
	May 31, 2018	May 31, 2017
Product sales	$ 14,188	$ 12,932
Licensing revenue	321,683	37,392
Freight revenue	1,062	756
Revenue	$ 336,933	$ 51,080

Schedule of Related Party Trans

Schedule of Related Party Transactions (Details) - USD ($)	9 Months Ended
	May 31, 2018	May 31, 2017
Related Party Transaction	$ 2,871,132	$ 303,165
Cash [Member]
Related Party Transaction	284,207	261,165
Non-Cash [Member]
Related Party Transaction	2,586,925	42,000
C.A.B Financial Services (CAB) [Member]
Related Party Transaction	1,110,705	100,000
C.A.B Financial Services (CAB) [Member] | Cash [Member]
Related Party Transaction	$ 108,000	$ 100,000
Percentage of Cash and Noncash Transaction	10.00%	100.00%
C.A.B Financial Services (CAB) [Member] | Non-Cash [Member]
Related Party Transaction	$ 1,002,705	$ 0
Percentage of Cash and Noncash Transaction	90.00%	0.00%
M&E Services Ltd. (M&E) [Member]
Related Party Transaction	$ 559,241	$ 35,311
M&E Services Ltd. (M&E) [Member] | Cash [Member]
Related Party Transaction	$ 58,140	$ 35,311
Percentage of Cash and Noncash Transaction	10.00%	100.00%
M&E Services Ltd. (M&E) [Member] | Non-Cash [Member]
Related Party Transaction	$ 501,101	$ 0
Percentage of Cash and Noncash Transaction	90.00%	0.00%
Docherty Management Limited (Docherty Management) [Member]
Related Party Transaction	$ 1,074,396	$ 131,854
Docherty Management Limited (Docherty Management) [Member] | Cash [Member]
Related Party Transaction	$ 106,067	$ 89,854
Percentage of Cash and Noncash Transaction	10.00%	68.00%
Docherty Management Limited (Docherty Management) [Member] | Non-Cash [Member]
Related Party Transaction	$ 968,329	$ 42,000
Percentage of Cash and Noncash Transaction	90.00%	32.00%
Company controlled by a director consulting [Member]
Related Party Transaction	$ 69,395	$ 36,000
Company controlled by a director consulting [Member] | Cash [Member]
Related Party Transaction	$ 12,000	$ 36,000
Percentage of Cash and Noncash Transaction	17.00%	100.00%
Company controlled by a director consulting [Member] | Non-Cash [Member]
Related Party Transaction	$ 57,395	$ 0
Percentage of Cash and Noncash Transaction	83.00%	0.00%
Director [Member]
Related Party Transaction	$ 57,395	$ 0
Director [Member] | Cash [Member]
Related Party Transaction	$ 0	$ 0
Percentage of Cash and Noncash Transaction	0.00%	0.00%
Director [Member] | Non-Cash [Member]
Related Party Transaction	$ 57,395	$ 0
Percentage of Cash and Noncash Transaction	100.00%	0.00%

Schedule of Segment Reporting I

Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	3 Months Ended		9 Months Ended
	May 31, 2018	May 31, 2017	May 31, 2018	May 31, 2017	Aug. 31, 2017
External Revenue	$ 140,340	$ 29,253	$ 336,933	$ 51,080
Cost of Goods Sold	(2,427)	(9,183)	(22,239)	(24,943)
Operating Expenses	(3,562,825)	(364,156)	(5,696,697)	(1,235,758)
Segment Loss	(3,424,912)	$ (344,086)	(5,382,003)	$ (1,209,621)
Total Assets	2,709,079		2,709,079		$ 2,860,178
Intellectual Property Licensing [Member]
External Revenue			321,683
Cost of Goods Sold			0
Operating Expenses			(1,712,237)
Segment Loss			(1,390,554)
Total Assets	120,567		120,567
Consumer Products [Member]
External Revenue			15,250
Cost of Goods Sold			(22,239)
Operating Expenses			(131,265)
Segment Loss			(138,254)
Total Assets	77,867		77,867
Corporate [Member]
Cost of Goods Sold			0
Operating Expenses			(3,853,195)
Segment Loss			(3,853,195)
Total Assets	$ 2,510,645		$ 2,510,645

Long-term Purchase Commitment (

Long-term Purchase Commitment (Details)	May 31, 2018USD ($)
Corporate Development [Member]
Monthly Commitment	$ 4,000
Corporate Development 2 [Member]
Monthly Commitment	1,000
Advisory Agreement [Member]
Monthly Commitment	4,000
Investor relations and communications Alex Blanchard Capital [Member]
Monthly Commitment	7,500
Office Management [Member]
Monthly Commitment	6,500
Research & Development [Member]
Monthly Commitment	3,854
C.A.B Financial Services (CAB) [Member]
Monthly Commitment	12,000
Docherty Management Limited (Docherty Management) [Member]
Monthly Commitment	15,000
M&E Services Ltd. (M&E) [Member]
Monthly Commitment	$ 8,000

Schedule of Prepaid Expenses (D

Schedule of Prepaid Expenses (Details) - USD ($)	May 31, 2018	Aug. 31, 2017
Advertising & Conferences	$ 98,385	$ 106,682
Consulting Fees	8,841	23,984
Office & Insurance	17,046	15,062
Legal Fees	37,610	3,963
Prepaid Expenses	$ 161,882	$ 149,691

Marketable Securities (Details)

Marketable Securities (Details) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2018	Aug. 31, 2017
Cost Basis	$ 25,000	$ 0
Unrealized Gains	0	0
Unrealized Losses	(7,383)	0
Marketable securities	$ 17,617	$ 0